Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group

SIMPLE SUMMARY: Azacitidine is thus far the only drug shown to prolong overall survival and is, therefore, the recommended (backbone) treatment in patients diagnosed with myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia who are not eligible for intensive chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Leisch, Michael, Pfeilstöcker, Michael, Stauder, Reinhard, Heibl, Sonja, Sill, Heinz, Girschikofsky, Michael, Stampfl-Mattersberger, Margarete, Tinchon, Christoph, Hartmann, Bernd, Petzer, Andreas, Schreder, Martin, Kiesl, David, Vallet, Sonia, Egle, Alexander, Melchardt, Thomas, Piringer, Gudrun, Zebisch, Armin, Machherndl-Spandl, Sigrid, Wolf, Dominik, Keil, Felix, Drost, Manuel, Greil, Richard, Pleyer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140081/
https://www.ncbi.nlm.nih.gov/pubmed/35626063
http://dx.doi.org/10.3390/cancers14102459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140081/
https://www.ncbi.nlm.nih.gov/pubmed/35626063
http://dx.doi.org/10.3390/cancers14102459

Ejemplares similares